Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.

In the past couple of years, it received approvals for several other new drugs like Kisunla, Omvoh and Jaypirca and witnessed ...

November is Alzheimer's Awareness Month and 7 News met Grand Island couple Tom and Michele Drabik, who shared their experience with the disease.

UK Regulator Approves Second Alzheimer's Drug in Months but Government Won't Pay for It LONDON (AP) — Britain's drug regulator approved the Alzheimer's drug Kisunla on Wednesday, but the ...

LONDON — Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn ...